Dendreon said it will push ahead with plans to seek FDA approval of its prostate cancer drug Provenge after discussing the latest Phase III data with regulators. Final results for Provenge were released at the European Cancer Conference in Paris. Earlier this year some analysts had noted that Dendreon might have to mount a third Phase III trial to satisfy the FDA.
- read this AP report for more